Search ABCL
AbCellera Biologics Inc.
Nasdaq · CIK 1703057
Last close13.74
Daily change-0.17 (-1.22%)
10 Years gain-76.67%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ABCL · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
39.6Momentum
100.0Acceleration
84.1Confidence
91.0Annual Revenue7
Quarterly Revenue20
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.7 / 25
Quality8.6 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics4.7 / 10
Forward Indicators3.6 / 5
Signals
Operating leverageOperating margin improved by 446.4006 percentage points.
ROIC expansionROIC improved by 2.0544 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM37.06%OK
Revenue CAGR 3Y-46.31%OK
Gross Margin100%OK
Operating Margin-640.97%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-21.62%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y2.64%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $75.13M | $75.13M | -$217.10M | -$131.30M | -$174.07M | 100% | -288.98% | -231.69% | -19.73% | 298.71M |
| 2025 FY Dec 31, 2024 | $28.83M | $28.83M | -$314.77M | -$108.56M | -$186.95M | 100% | -1,091.69% | -648.4% | -25.92% | 294.33M |
| 2025 FY Dec 31, 2023 | $38.03M | $38.03M | -$237.21M | -$43.88M | -$120.82M | 100% | -623.82% | -317.75% | -20.09% | 289.17M |
| 2024 FY Dec 31, 2022 | $485.42M | $485.42M | $216.51M | $277.36M | $206.70M | 100% | 44.6% | 42.58% | 20.56% | 314.83M |
| 2023 FY Dec 31, 2021 | $375.20M | $375.20M | $204.41M | $244.58M | $186.13M | 100% | 54.48% | 49.61% | 36.42% | 318.29M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $38.40M | sum latest 4 fiscal quarters Revenue | OK | 0001703057-26-000046, 0001703057-25-000025 |
| Revenue Growth TTM | 37.06% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001703057-26-000046, 0001703057-25-000025 |
| Revenue CAGR 3Y | -46.31% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001703057-26-000012 |
| Revenue CAGR 5Y | -20.27% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001703057-26-000012 |
| Gross Profit CAGR 3Y | -46.31% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001703057-26-000012 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001703057-26-000046, 0001703057-25-000025 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001703057-26-000046, 0001703057-25-000025 |
| Operating Margin | -640.97% | Operating Income / Revenue | OK | 0001703057-26-000046, 0001703057-25-000025 |
| ROIC | -21.62% | NOPAT / Average Invested Capital | OK | 0001703057-26-000046, 0001703057-25-000025 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001703057-26-000046 |
| Current Ratio | 12.77x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.13 | Revenue / Diluted Shares | OK | 0001703057-26-000046, 0001703057-25-000025 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |